Chelsea M. Magin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chelsea M. Magin has a total of 237 co-authors. Here are the top co-authors by number of shared publications:
Rachel Blomberg
University of Colorado
16 shared publicationsMikala C. Mueller
University of Colorado
9 shared publicationsAlicia E. Tanneberger
Department of Biomedical Engineering, University of Colorado, Denver | Anschutz, Aurora, CO, USA
7 shared publicationsAnthony B. Brennan
Department of Materials Science & Engineering, University of Florida, Gainesville, USA
7 shared publicationsHaley Noelle
Department of Biomedical Engineering, University of Colorado, Denver | Anschutz
6 shared publicationsDuncan Davis-Hall
Department of Bioengineering, University of Colorado, Denver | Anschutz Medical Campus
5 shared publications
Latest Publications
- 12 November 2026
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
Proteomic analysis reveals regional sex differences in healthy and fibrotic human lung
Biological sex has systemic effects on gene expression, cell behavior, and disease pathobiology. Despite these widespread effects, sex as a biological variable remains understudied, particularly in chronic lung diseases. In idiopathic pulmonary fibrosis (IPF), approximately 70% of patients are male, and male patients have overall worse survival following diagnosis. While behavioral differences between sexes might account for some of the epidemiological differences, the contribution of underlying biology is not known. In this study, we re-analyzed a previously generated regional proteomic dataset obtained by laser capture microdissection coupled with mass spectrometry to identify sex-associated differences in protein abundance. We discovered that even in control lungs, sex differences existed in both airway and alveolar regions. Sex differences became more pronounced in diseased regions of IPF lungs, with sex-biased abundance of diverse proteins including those associated with extracellular vesicle secretion, cellular metabolism, and extracellular matrix remodeling. Together, these findings demonstrate region-specific and disease-associated sex differences in the human lung proteome and suggest that baseline sex differences in control lungs may contribute to sex-specific susceptibility, progression, and clinical outcomes in IPF, underscoring the importance of considering sex as a biological variable in future mechanistic and clinical studies of IPF.
- 12 November 2026
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
Proteomic analysis reveals regional sex differences in healthy and fibrotic human lung
Biological sex has systemic effects on gene expression, cell behavior, and disease pathobiology. Despite these widespread effects, sex as a biological variable remains understudied, particularly in chronic lung diseases. In idiopathic pulmonary fibrosis (IPF), approximately 70% of patients are male, and male patients have overall worse survival following diagnosis. While behavioral differences between sexes might account for some of the epidemiological differences, the contribution of underlying biology is not known. In this study, we re-analyzed a previously generated regional proteomic dataset obtained by laser capture microdissection coupled with mass spectrometry to identify sex-associated differences in protein abundance. We discovered that even in control lungs, sex differences existed in both airway and alveolar regions. Sex differences became more pronounced in diseased regions of IPF lungs, with sex-biased abundance of diverse proteins including those associated with extracellular vesicle secretion, cellular metabolism, and extracellular matrix remodeling. Together, these findings demonstrate region-specific and disease-associated sex differences in the human lung proteome and suggest that baseline sex differences in control lungs may contribute to sex-specific susceptibility, progression, and clinical outcomes in IPF, underscoring the importance of considering sex as a biological variable in future mechanistic and clinical studies of IPF.
- Open Access
Translating Sex- and Disease-Informed Design Criteria from Human Lung into Engineered Biomaterials
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterized by pathological extracellular matrix (ECM) remodeling, and a pronounced sex disparity, with approximately 70% of cases occurring in males. Despite these differences, biomaterials used to model fibrosis are commonly designed to replicate disease state or stiffness alone and rarely account for biological sex. Here, we derived sex- and disease-informed biomaterial design criteria from female and male control and IPF human lungs and translated these criteria into engineered hybrid-hydrogels containing human lung decellularized ECM (dECM) and poly(ethylene glycol) alpha methacrylate (PEG⍰MA). Matrisome-focused reanalysis of our previously published region-resolved human lung proteomic dataset revealed region- and sex-associated differences in fibrillar collagens, matricellular proteins, and structural proteoglycans. Complementary characterization of human lung tissue further identified sex- and disease-associated differences in fibrillar collagen architecture, proteoglycan and glycosaminoglycan (GAG) remodeling, and tissue mechanics. Male IPF lungs exhibited the highest levels of disease-associated stiffening and fibrillar collagen remodeling, while female IPF tissue showed comparatively modest mechanical changes despite biochemical remodeling. These measurements established tissue-informed design criteria spanning matrix composition, architecture, and mechanics. We next evaluated whether tissue-derived properties were reproduced or retained following decellularization, processing, and incorporation of donor-derived dECM into hybrid-hydrogels. Engineered hybrid-hydrogels closely recapitulated sex- and disease-associated mechanical relationships, while COL1A1-associated abundance patterns were more consistently preserved than fibrillar collagen organization. Matricellular proteins and GAG-rich matrix remained detectable, although condition-dependent biochemical fidelity varied. This work establishes a human tissue-informed framework for engineering sex- and disease-specific biomaterials, highlighting the importance of defining sex-associated ECM properties and validating individual features following material fabrication to advance human models of IPF and other diseases with sex-associated differences in susceptibility and progression.
Open AccessTranslating Sex- and Disease-Informed Design Criteria from Human Lung into Engineered Biomaterials
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease characterized by pathological extracellular matrix (ECM) remodeling, and a pronounced sex disparity, with approximately 70% of cases occurring in males. Despite these differences, biomaterials used to model fibrosis are commonly designed to replicate disease state or stiffness alone and rarely account for biological sex. Here, we derived sex- and disease-informed biomaterial design criteria from female and male control and IPF human lungs and translated these criteria into engineered hybrid-hydrogels containing human lung decellularized ECM (dECM) and poly(ethylene glycol) alpha methacrylate (PEG⍰MA). Matrisome-focused reanalysis of our previously published region-resolved human lung proteomic dataset revealed region- and sex-associated differences in fibrillar collagens, matricellular proteins, and structural proteoglycans. Complementary characterization of human lung tissue further identified sex- and disease-associated differences in fibrillar collagen architecture, proteoglycan and glycosaminoglycan (GAG) remodeling, and tissue mechanics. Male IPF lungs exhibited the highest levels of disease-associated stiffening and fibrillar collagen remodeling, while female IPF tissue showed comparatively modest mechanical changes despite biochemical remodeling. These measurements established tissue-informed design criteria spanning matrix composition, architecture, and mechanics. We next evaluated whether tissue-derived properties were reproduced or retained following decellularization, processing, and incorporation of donor-derived dECM into hybrid-hydrogels. Engineered hybrid-hydrogels closely recapitulated sex- and disease-associated mechanical relationships, while COL1A1-associated abundance patterns were more consistently preserved than fibrillar collagen organization. Matricellular proteins and GAG-rich matrix remained detectable, although condition-dependent biochemical fidelity varied. This work establishes a human tissue-informed framework for engineering sex- and disease-specific biomaterials, highlighting the importance of defining sex-associated ECM properties and validating individual features following material fabrication to advance human models of IPF and other diseases with sex-associated differences in susceptibility and progression.
- 24 July 2026
- Published by American Society of Hematology in Blood
Factor V is an anticoagulant of the extrinsic pathway of coagulation and modifier of thrombin generation in hemophilia A
Factor V (FV) links procoagulant amplification to anticoagulant feedback, but how FV limits tissue factor-initiated coagulation are not fully defined. We hypothesized that procofactor FV downregulates factor X (FX) activation by tissue factor:factor VIIa (TF:FVIIa), independently of tissue factor pathway inhibitor α (TFPIα), and that this mechanism is especially important in hemophilia. Thrombin generation was measured in FV/FVIII‑immunodepleted plasma and synthetic plasma while titrating FV, with TFPIα removed, blocked, or re-added. TF:FVIIa activation of FX was measured on phosphatidylserine‑containing or phosphatidylserine‑free liposomes with antibodies against the FV light chain and C2 domain. FV and TFPIα levels modulated thrombin generation in plasma from people with hemophilia A. In TF‑initiated coagulation lacking TFPIα, thrombin generation peaked at 2 nM FV and decreased as FV increased; at 20 nM FV (normal concentration), peak thrombin and thrombin generation rate were reduced by up to 50-80%, with larger effects at low FVIII. In purified TF:FVIIa assays, FV reduced FX activation by ~80% at physiologic concentration and inhibited FX activation on TF-expressing fibroblasts. Increasing PS content enhanced FX activation and increased the FV-sensitive component, while blocking the FV light chain or C2 domain partially relieved inhibition. In hemophilia A plasma, higher FV was associated with longer lag time and time-to-peak, and lower peak thrombin independent of TFPIα. Thus, FV is an endogenous anticoagulant that inhibits TF-initiated coagulation by limiting FX activation by TF:FVIIa through a membrane-dependent mechanism. This mechanism refines models of coagulation initiation and may help explain how FV variation contributes to bleeding and thrombosis.
- 24 July 2026
- Published by American Society of Hematology in Blood
Factor V is an anticoagulant of the extrinsic pathway of coagulation and modifier of thrombin generation in hemophilia A
Factor V (FV) links procoagulant amplification to anticoagulant feedback, but how FV limits tissue factor-initiated coagulation are not fully defined. We hypothesized that procofactor FV downregulates factor X (FX) activation by tissue factor:factor VIIa (TF:FVIIa), independently of tissue factor pathway inhibitor α (TFPIα), and that this mechanism is especially important in hemophilia. Thrombin generation was measured in FV/FVIII‑immunodepleted plasma and synthetic plasma while titrating FV, with TFPIα removed, blocked, or re-added. TF:FVIIa activation of FX was measured on phosphatidylserine‑containing or phosphatidylserine‑free liposomes with antibodies against the FV light chain and C2 domain. FV and TFPIα levels modulated thrombin generation in plasma from people with hemophilia A. In TF‑initiated coagulation lacking TFPIα, thrombin generation peaked at 2 nM FV and decreased as FV increased; at 20 nM FV (normal concentration), peak thrombin and thrombin generation rate were reduced by up to 50-80%, with larger effects at low FVIII. In purified TF:FVIIa assays, FV reduced FX activation by ~80% at physiologic concentration and inhibited FX activation on TF-expressing fibroblasts. Increasing PS content enhanced FX activation and increased the FV-sensitive component, while blocking the FV light chain or C2 domain partially relieved inhibition. In hemophilia A plasma, higher FV was associated with longer lag time and time-to-peak, and lower peak thrombin independent of TFPIα. Thus, FV is an endogenous anticoagulant that inhibits TF-initiated coagulation by limiting FX activation by TF:FVIIa through a membrane-dependent mechanism. This mechanism refines models of coagulation initiation and may help explain how FV variation contributes to bleeding and thrombosis.
- Open Access
Dynamic hybrid-hydrogel lung models decouple matrix composition, stiffness, and fibroblast conditioning to define distinct drivers of fibrotic progression
Idiopathic pulmonary fibrosis is a devastating chronic lung disease characterized by progressive scarring of the lung, which leads to impaired gas exchange and ultimately death. While research has provided us with extensive understanding on end-stage disease, the factors that lead to forward-feedback loops of fibrotic progression are still not fully known. Cell intrinsic phenotype, pathological extracellular matrix (ECM) composition, and increased tissue stiffness are all hallmarks of advanced fibrosis, but the relative contribution of these factors to disease has been difficult to disentangle using classic in vivo models. In this study we created biomaterials-based 3D lung models that incorporate geometrically relevant co-culture of lung epithelial cells and fibroblasts with tunable stiffness, ECM-containing hybrid-hydrogels. Using this model system, we demonstrated that environmental stiffness has the strongest effect on overall fibroblast phenotype. RNAseq analysis revealed unique gene-level changes in both fibroblasts and epithelial cells due to both composition and stiffness, highlighting the importance of incorporating both factors into any in vivo disease models. Overall, these results reinforce the value of biomaterials-based models in understanding and disentangling contributors to disease pathogenesis.
Open AccessDynamic hybrid-hydrogel lung models decouple matrix composition, stiffness, and fibroblast conditioning to define distinct drivers of fibrotic progression
Idiopathic pulmonary fibrosis is a devastating chronic lung disease characterized by progressive scarring of the lung, which leads to impaired gas exchange and ultimately death. While research has provided us with extensive understanding on end-stage disease, the factors that lead to forward-feedback loops of fibrotic progression are still not fully known. Cell intrinsic phenotype, pathological extracellular matrix (ECM) composition, and increased tissue stiffness are all hallmarks of advanced fibrosis, but the relative contribution of these factors to disease has been difficult to disentangle using classic in vivo models. In this study we created biomaterials-based 3D lung models that incorporate geometrically relevant co-culture of lung epithelial cells and fibroblasts with tunable stiffness, ECM-containing hybrid-hydrogels. Using this model system, we demonstrated that environmental stiffness has the strongest effect on overall fibroblast phenotype. RNAseq analysis revealed unique gene-level changes in both fibroblasts and epithelial cells due to both composition and stiffness, highlighting the importance of incorporating both factors into any in vivo disease models. Overall, these results reinforce the value of biomaterials-based models in understanding and disentangling contributors to disease pathogenesis.
- Open Access
- 1 June 2026
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 330 (6) , L708-L712
The importance of sex as a biological variable in pulmonary vascular research
Sex differences shape disease susceptibility, progression, and therapeutic response across human health, yet their systematic integration into biomedical research remains uneven. In preclinical stu...
- 1 June 2026
- Published by American Physiological Society in American Journal of Physiology-Lung Cellular and Molecular Physiology
- Vol. 330 (6) , L708-L712
Open AccessThe importance of sex as a biological variable in pulmonary vascular research
Sex differences shape disease susceptibility, progression, and therapeutic response across human health, yet their systematic integration into biomedical research remains uneven. In preclinical stu...
- Open Access
Proteomic analysis reveals regional sex differences in healthy and fibrotic human lung
Biological sex has systemic effects on gene expression, cell behavior, and disease etiology. Despite these widespread effects, sex as a biological variable is understudied, particularly in chronic lung diseases. In idiopathic pulmonary fibrosis (IPF), 70% of patients are male, and male patients have overall worse survival post-diagnosis. While behavioral differences between sexes might account for some of the epidemiological differences, the contribution of underlying biology is not known. In this study, we performed regional proteomic analysis via laser-captured microdissection-coupled mass spectrometry and analyzed the data for sex-biased protein expression. We discovered that even in control lung, sex differences existed in both airway and alveolar regions. Sex differences became more pronounced in diseased regions, with sex-biased expression of diverse proteins including those involved in extracellular vesicle secretion, cellular metabolism, and extracellular matrix remodeling. These data suggest that baseline sex differences in lung proteome may contribute to sex-specific susceptibility, progression, and clinical outcomes in IPF, underscoring the need for future mechanistic and clinical studies to account for sex as a biological variable.
Open AccessProteomic analysis reveals regional sex differences in healthy and fibrotic human lung
Biological sex has systemic effects on gene expression, cell behavior, and disease etiology. Despite these widespread effects, sex as a biological variable is understudied, particularly in chronic lung diseases. In idiopathic pulmonary fibrosis (IPF), 70% of patients are male, and male patients have overall worse survival post-diagnosis. While behavioral differences between sexes might account for some of the epidemiological differences, the contribution of underlying biology is not known. In this study, we performed regional proteomic analysis via laser-captured microdissection-coupled mass spectrometry and analyzed the data for sex-biased protein expression. We discovered that even in control lung, sex differences existed in both airway and alveolar regions. Sex differences became more pronounced in diseased regions, with sex-biased expression of diverse proteins including those involved in extracellular vesicle secretion, cellular metabolism, and extracellular matrix remodeling. These data suggest that baseline sex differences in lung proteome may contribute to sex-specific susceptibility, progression, and clinical outcomes in IPF, underscoring the need for future mechanistic and clinical studies to account for sex as a biological variable.
- Open Access
Hydrogel-Embedded Precision-Cut Lung Slices Recapitulate Fibrotic Gene Expression and Enable Therapeutic Response Evaluation
Precision-cut lung slices (PCLS) retain the native cells and extracellular matrix that contribute to the structural and functional integrity of lung tissue. This technique enables the study of cell-matrix interactions and is particularly useful for pre-clinical pharmacological studies. More specifically, PCLS are widely used to model the complex pathophysiology of pulmonary fibrosis, an uncurable and progressive interstitial lung disease. Current ex vivo pulmonary fibrosis models expose PCLS to pro-fibrotic biochemical cues over a short timeframe (hours to days) and quickly collect samples for analysis due to viability concerns. This condensed timeline is a limitation to understanding chronic disease mechanisms. To extend the utility of ex vivo pulmonary fibrosis models, PCLS were embedded in engineered hydrogels and exposed to pro-fibrotic biochemical and biophysical cues. Hydrogel-embedded PCLS maintained greater than 80% total cell viability over 3 weeks in culture. Gene expression patterns in samples exposed to pro-fibrotic cues matched trends measured in human fibrotic lung tissue. Finally, treatment with Nintedanib, a Food and Drug Administration approved pulmonary fibrosis drug, moderately reduced fibroblast activation and influenced epithelial cell differentiation. Collectively, these results show that hydrogel-embedded PCLS models of pulmonary fibrosis extend our ability to study fibrotic processes ex vivo and, when applied to human tissues, present a new approach methodology for studying lung disease and treatment.
Open AccessHydrogel-Embedded Precision-Cut Lung Slices Recapitulate Fibrotic Gene Expression and Enable Therapeutic Response Evaluation
Precision-cut lung slices (PCLS) retain the native cells and extracellular matrix that contribute to the structural and functional integrity of lung tissue. This technique enables the study of cell-matrix interactions and is particularly useful for pre-clinical pharmacological studies. More specifically, PCLS are widely used to model the complex pathophysiology of pulmonary fibrosis, an uncurable and progressive interstitial lung disease. Current ex vivo pulmonary fibrosis models expose PCLS to pro-fibrotic biochemical cues over a short timeframe (hours to days) and quickly collect samples for analysis due to viability concerns. This condensed timeline is a limitation to understanding chronic disease mechanisms. To extend the utility of ex vivo pulmonary fibrosis models, PCLS were embedded in engineered hydrogels and exposed to pro-fibrotic biochemical and biophysical cues. Hydrogel-embedded PCLS maintained greater than 80% total cell viability over 3 weeks in culture. Gene expression patterns in samples exposed to pro-fibrotic cues matched trends measured in human fibrotic lung tissue. Finally, treatment with Nintedanib, a Food and Drug Administration approved pulmonary fibrosis drug, moderately reduced fibroblast activation and influenced epithelial cell differentiation. Collectively, these results show that hydrogel-embedded PCLS models of pulmonary fibrosis extend our ability to study fibrotic processes ex vivo and, when applied to human tissues, present a new approach methodology for studying lung disease and treatment.
- 7 August 2025
- Published by Elsevier in Acta Biomaterialia
- Vol. 204, 277-292
Biomaterial-based 3D human lung models replicate pathological characteristics of early pulmonary fibrosis
- 7 August 2025
- Published by Elsevier in Acta Biomaterialia
- Vol. 204, 277-292
Biomaterial-based 3D human lung models replicate pathological characteristics of early pulmonary fibrosis
- Open Access
- 12 July 2025
- Published by Wiley in Physiological Reports
- Vol. 13 (13) , e70459
Hydrogel‐embedded precision‐cut lung slices support ex vivo culture of in vivo‐induced premalignant lung lesions
Lung cancer is the leading cause of global cancer death, and prevention strategies are key to reducing mortality. Medical prevention of premalignant lesion (PML) progression may have a larger impact than treatment on mortality by targeting high‐risk populations and reducing their lung cancer risk. PMLs are difficult to study in humans but are easily accessible in murine preclinical carcinogenesis studies. Precision‐cut lung slices (PCLS) are underutilized as an ex vivo model for lung cancer studies due to limited culture time. Embedding PCLS within bioengineered hydrogels extends PCLS viability and functionality for up to 6 weeks. Here, we embedded PCLS with PMLs generated from urethane‐exposed mice in cell‐degradable and nondegradable hydrogels to study viability and responsiveness to PML interception over 6 weeks. PMLs in hydrogel‐embedded PCLS maintained viability, gene expression, and proliferation. Treatment of hydrogel‐embedded PCLS containing urethane‐induced PMLs with iloprost, a known lung cancer prevention agent, recapitulated in vivo gene expression and activity. Our studies also showed that iloprost reduced proliferation and PML size in PCLS embedded in degradable hydrogels. These results demonstrate that hydrogel‐embedded PCLS models support long‐term culture of in vivo generated PMLs. This modeling approach will improve preclinical studies of cancer biology and prevention across cancer types.
- 12 July 2025
- Published by Wiley in Physiological Reports
- Vol. 13 (13) , e70459
Open AccessHydrogel‐embedded precision‐cut lung slices support ex vivo culture of in vivo‐induced premalignant lung lesions
Lung cancer is the leading cause of global cancer death, and prevention strategies are key to reducing mortality. Medical prevention of premalignant lesion (PML) progression may have a larger impact than treatment on mortality by targeting high‐risk populations and reducing their lung cancer risk. PMLs are difficult to study in humans but are easily accessible in murine preclinical carcinogenesis studies. Precision‐cut lung slices (PCLS) are underutilized as an ex vivo model for lung cancer studies due to limited culture time. Embedding PCLS within bioengineered hydrogels extends PCLS viability and functionality for up to 6 weeks. Here, we embedded PCLS with PMLs generated from urethane‐exposed mice in cell‐degradable and nondegradable hydrogels to study viability and responsiveness to PML interception over 6 weeks. PMLs in hydrogel‐embedded PCLS maintained viability, gene expression, and proliferation. Treatment of hydrogel‐embedded PCLS containing urethane‐induced PMLs with iloprost, a known lung cancer prevention agent, recapitulated in vivo gene expression and activity. Our studies also showed that iloprost reduced proliferation and PML size in PCLS embedded in degradable hydrogels. These results demonstrate that hydrogel‐embedded PCLS models support long‐term culture of in vivo generated PMLs. This modeling approach will improve preclinical studies of cancer biology and prevention across cancer types.
- Open Access
- 12 June 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (14)
The MUC5B promoter variant results in proteomic changes in the nonfibrotic lung
The gain-of-function MUC5B promoter variant is the dominant risk factor for the development of idiopathic pulmonary fibrosis (IPF). However, its impact on protein expression in both nonfibrotic control and IPF lung specimens has not been well characterized. Utilizing laser capture microdissection coupled to mass spectrometry, we investigated the proteomic profiles of airway and alveolar epithelium in nonfibrotic controls ( n = 12) and IPF specimens ( n = 12), stratified by the MUC5B promoter variant. Through qualitative and quantitative analyses, as well as pathway analysis and immunohistological validation, we have identified a distinct MUC5B-associated protein profile. Notably, the nonfibrotic control alveoli exhibited substantial MUC5B-associated protein changes, with an increase in IL-3 signaling. Additionally, we found that epithelial cells overlying IPF fibroblastic foci clustered closely to alveolar epithelia and expressed proteins associated with cellular stress pathways. In conclusion, our findings suggest that the MUC5B promoter variant leads to protein changes in alveolar and airway epithelium that appear to be associated with initiation and progression of lung fibrosis.
- 12 June 2025
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 10 (14)
Open AccessThe MUC5B promoter variant results in proteomic changes in the nonfibrotic lung
The gain-of-function MUC5B promoter variant is the dominant risk factor for the development of idiopathic pulmonary fibrosis (IPF). However, its impact on protein expression in both nonfibrotic control and IPF lung specimens has not been well characterized. Utilizing laser capture microdissection coupled to mass spectrometry, we investigated the proteomic profiles of airway and alveolar epithelium in nonfibrotic controls ( n = 12) and IPF specimens ( n = 12), stratified by the MUC5B promoter variant. Through qualitative and quantitative analyses, as well as pathway analysis and immunohistological validation, we have identified a distinct MUC5B-associated protein profile. Notably, the nonfibrotic control alveoli exhibited substantial MUC5B-associated protein changes, with an increase in IL-3 signaling. Additionally, we found that epithelial cells overlying IPF fibroblastic foci clustered closely to alveolar epithelia and expressed proteins associated with cellular stress pathways. In conclusion, our findings suggest that the MUC5B promoter variant leads to protein changes in alveolar and airway epithelium that appear to be associated with initiation and progression of lung fibrosis.